MDMA filing incoming for PTSD as further trial delivers
The MAPS Public Benefit Corporation - a subsidiary of the Multidisciplinary Association for Psychedelic Studies - appears to be moving ever closer to an attention-grabbing approval for MDMA (3,4-methylenedioxy-methamphetamine).
Data from the company’s MAPP2 trial, a multi-site Phase III study of MDMA-assisted therapy for post–traumatic stress disorder (PTSD), has been published in the September issue of Nature Medicine.
The MAPP2 study met its primary and secondary endpoints confirming the results seen in the first Phase III study, MAPP1, that were also published in Nature Medicine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze